» Articles » PMID: 32009959

MiR-124 and the Underlying Therapeutic Promise of Neurodegenerative Disorders

Overview
Journal Front Pharmacol
Date 2020 Feb 4
PMID 32009959
Citations 31
Authors
Affiliations
Soon will be listed here.
Abstract

Neurodegenerative disorders (NDDs) are a group of chronic progressive neurological diseases based on primary neurodegeneration. The common pathological characteristics of various NDDs are neuronal degeneration, deletion, glial cell proliferation, and hypertrophy at specific locations in the nervous system. Proliferation and hypertrophy of microglia are manifestations of inflammation. MicroRNAs (miRNAs) have emerged as pivotal regulators of glial cells. MiRNAs are small non-coding molecules that regulate gene expression. Altered expression of miRNAs has been associated with several NDD pathological processes, among which regulation of the inflammatory response is key and a research hotspot at present. At the same time, miRNAs are also biological markers for diagnosis and potential targets for treating NDDs. MiR-124 is highly conserved and enriched in the mammalian brain. Emerging studies have suggested that miR-124 is closely related to the pathogenesis of NDDs and may be an effective treatment strategy to reduce inflammation associated with NDDs. In this review, we describe a summary of general miRNA biology, implications in pathophysiology, the potential roles of miR-124 associated with inflammation, and the use of miRNA as a future biomarker and an application for NDD therapy.

Citing Articles

Cell-Free Nucleic Acids for Early Diagnosis of Acute Ischemic Stroke: A Systematic Review and Meta-Analysis.

Zhang X, Cai Y, Sit B, Jian R, Malki Y, Zhang Y Int J Mol Sci. 2025; 26(4).

PMID: 40003998 PMC: 11855205. DOI: 10.3390/ijms26041530.


miRNA in blood-brain barrier repair: role of extracellular vesicles in stroke recovery.

Sprincl V, Romanyuk N Front Cell Neurosci. 2025; 19:1503193.

PMID: 39990970 PMC: 11842324. DOI: 10.3389/fncel.2025.1503193.


Targeting Invasion: The Role of MMP-2 and MMP-9 Inhibition in Colorectal Cancer Therapy.

Shoari A, Ashja Ardalan A, Dimesa A, Coban M Biomolecules. 2025; 15(1).

PMID: 39858430 PMC: 11762759. DOI: 10.3390/biom15010035.


MicroRNA Nobel Prize: Timely Recognition and High Anticipation of Future Products-A Prospective Analysis.

Niazi S, Magoola M Int J Mol Sci. 2024; 25(23.

PMID: 39684593 PMC: 11641023. DOI: 10.3390/ijms252312883.


Single-nucleus multi-omics analyses reveal cellular and molecular innovations in the anterior cingulate cortex during primate evolution.

Yuan J, Dong K, Wu H, Zeng X, Liu X, Liu Y Cell Genom. 2024; 4(12):100703.

PMID: 39631404 PMC: 11701334. DOI: 10.1016/j.xgen.2024.100703.


References
1.
Saraiva C, Ferreira L, Bernardino L . Traceable microRNA-124 loaded nanoparticles as a new promising therapeutic tool for Parkinson's disease. Neurogenesis (Austin). 2017; 3(1):e1256855. PMC: 5384609. DOI: 10.1080/23262133.2016.1256855. View

2.
Torrisi L . Gold nanoparticles enhancing protontherapy efficiency. Recent Pat Nanotechnol. 2015; 9(1):51-60. DOI: 10.2174/1872210509999141222224121. View

3.
Yang H, Yang S, Huang S, Tang B, Guo J . Microglial Activation in the Pathogenesis of Huntington's Disease. Front Aging Neurosci. 2017; 9:193. PMC: 5474461. DOI: 10.3389/fnagi.2017.00193. View

4.
Smith P, Al Hashimi A, Girard J, Delay C, Hebert S . In vivo regulation of amyloid precursor protein neuronal splicing by microRNAs. J Neurochem. 2010; 116(2):240-7. DOI: 10.1111/j.1471-4159.2010.07097.x. View

5.
Smirnova L, Grafe A, Seiler A, Schumacher S, Nitsch R, Wulczyn F . Regulation of miRNA expression during neural cell specification. Eur J Neurosci. 2005; 21(6):1469-77. DOI: 10.1111/j.1460-9568.2005.03978.x. View